29Jul
National Retailer Pulls CBD Products From Shelves in Response to FDA Warning to Product Manufacturer
On Monday, July 22, the U.S. Food and Drug Administration (FDA) took a rare and significant step in issuing a warning letter to Curaleaf Holdings, Inc. (Curaleaf), one of the country’s larger producers of CBD-based products, regarding Curaleaf’s...
By:
Manatt, Phelps & Phillips, LLP
Related
The production tax credit for renewable wind projects under Section 45 of the Internal Revenue Code ...
Read More >
Executive Summary. On May 21, 2020, the Securities and Exchange Commission (SEC) adopted amendments ...
Read More >
Reporting Harassment to Third Parties Constitutes Slander - Precedential Decision by Judiciary or R...
Read More >
For contractors and subcontractors, late payments can be an all-too-familiar part of the constructio...
Read More >
ICE is now conducting worksite inspections for STEM OPT employers. ICE’s stated purpose for conduct...
Read More >
One of the areas articulated in the 2019 Guidance was around payments and payroll. For both the comp...
Read More >